Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 80
Filtrar
Más filtros

Intervalo de año de publicación
1.
Acta Derm Venereol ; 104: adv19663, 2024 06 11.
Artículo en Inglés | MEDLINE | ID: mdl-38860622

RESUMEN

The MDHHgermany registry was initiated to characterize the "real-life" situation of affected individuals with Darier's disease (DD; Morbus Darier, MD) and Hailey-Hailey disease (HH), including their treatment and healthcare. To gain deeper insights into medical care of patients with DD, various aspects such as demographics, subjective symptoms, patient satisfaction with medical care, past and current therapies were explored. Patients with diagnosed DD were included. Subjective symptoms such as itch, pain and burning sensation were assessed. Individual therapy goals were recorded and patients assessed previous/current therapies along with satisfaction of medical care and treatment. A total of 55 patients were recruited; 47 patients were eligible for the analysis. Pruritus was rated the most bothersome symptom. Some 42.6% had not received systemic treatment so far or systemic therapies were rated ineffective (32.6%). Most commonly oral retinoids were prescribed, followed by corticosteroids. Patient satisfaction with medical care and treatment proved to be mediocre. This "real-life" data show an alarming unmet need regarding patients' satisfaction with medical care and treatment, evidenced by the reported lack of disease control. Further studies and interventions are needed to improve the spectrum of available therapies. MDHHgermany provides a foundational platform for future clinical trials, epidemiological studies, and pathophysiological analyses.


Asunto(s)
Enfermedad de Darier , Satisfacción del Paciente , Sistema de Registros , Humanos , Enfermedad de Darier/terapia , Enfermedad de Darier/diagnóstico , Enfermedad de Darier/tratamiento farmacológico , Masculino , Femenino , Alemania , Persona de Mediana Edad , Anciano , Adulto , Resultado del Tratamiento , Necesidades y Demandas de Servicios de Salud , Pénfigo Familiar Benigno/diagnóstico , Pénfigo Familiar Benigno/tratamiento farmacológico , Pénfigo Familiar Benigno/terapia , Prurito/etiología , Evaluación de Necesidades , Corticoesteroides/uso terapéutico , Retinoides/uso terapéutico
2.
Clin Exp Dermatol ; 49(10): 1105-1117, 2024 Sep 18.
Artículo en Inglés | MEDLINE | ID: mdl-38447098

RESUMEN

This review aims to present a comprehensive synthesis of the existing treatment modalities for keratosis pilaris (KP) and evaluate their therapeutic efficacy. KP is a prevalent chronic dermatological condition typified by its unique 'chicken skin appearance', with the cheeks being the most commonly involved sites. Numerous therapeutic interventions have emerged, given its substantial prevalence and impact on skin aesthetics and psychological wellbeing. Nonetheless, a consistent therapeutic response has been challenging to achieve. This review endeavours to collate and critically appraise the current treatment landscape for KP. An exhaustive literature search was performed using databases such as Ovid, PubMed and Scopus. From an initial count of 459 articles identified after deduplication, 52 were selected for inclusion after a thorough full-text examination for articles with concrete outcome data highlighting the efficacies of different therapeutic modalities; articles that lacked data or were tangential to the core focus on KP treatment were excluded. The included articles were then catalogued based on the nature of treatment strategies and their respective outcomes. Among the various therapeutic interventions, laser and light modalities appear to be supported by the most substantial evidence base. Notably, the Nd:YAG (neodymium-doped yttrium-aluminium-garnet) laser, attributed to its longer wavelength, emerged as a preferred option. While other therapeutic avenues have also exhibited notable improvements in skin texture and discolouration relative to baseline, the inconsistency in outcome measures underscores the need for a standardized, KP-specific scoring system to foster a more coherent comparison across treatments. Based on the current evidence, Nd:YAG laser therapy demonstrates promising effectiveness with a relatively favourable side-effect profile. However, the landscape of KP treatment is multifaceted, and further studies are essential to solidify recommendations.


Asunto(s)
Enfermedad de Darier , Cejas , Humanos , Cejas/anomalías , Enfermedad de Darier/terapia , Enfermedad de Darier/patología , Enfermedad de Darier/diagnóstico , Anomalías Cutáneas/terapia , Anomalías Cutáneas/patología , Anomalías Múltiples/terapia , Resultado del Tratamiento , Láseres de Estado Sólido/uso terapéutico , Fototerapia/métodos , Terapia por Láser/métodos
3.
Rev Med Suisse ; 20(867): 659-663, 2024 Mar 27.
Artículo en Francés | MEDLINE | ID: mdl-38563541

RESUMEN

Darier Disease is a rare autosomal dominant inherited skin disorder classified as an acantholytic dermatosis. It manifests around puberty as brownish keratotic papules of skin folds and seborrheic areas, associated with onychopathy and mucosal involvementand have a chronic relapsing-remitting course with frequent exacerbations triggered by sun exposure, heat, friction, or infections. Darier patients have an increased risk of neuropsychiatric disorders, type 1 diabetes and heart failure. Short-term management relies on antibiotics/antiviral, topical corticosteroids and/or retinoids. Moisturizers, sun protection and avoiding triggers are essential for long-term management. Conventional long-term treatment is not standardized and many topical treatments, physical and surgical measures and systemic treatments are described in the literature.


La maladie de Darier est une génodermatose rare à transmission autosomique dominante. Elle se manifeste autour de la puberté par des papules kératosiques brunâtres des plis et des zones séborrhéiques, associées à une onychopathie et une atteinte muqueuse, et évolue par poussées déclenchées par les UV, la chaleur, les frottements ou les infections. Les patients atteints présentent un risque accru de diabète de type 1, d'insuffisance cardiaque et de troubles neuropsychiatriques. La prise en charge à court terme consiste en des antibiotiques/antiviraux, des corticostéroïdes topiques et/ou des rétinoïdes. Celle à long terme repose sur les émollients et l'éviction des facteurs déclenchants. Le traitement à long terme n'étant pas codifié, de nombreux traitements locaux et sytémiques, mesures physiques et chirurgicales sont décrits dans la littérature.


Asunto(s)
Enfermedad de Darier , Humanos , Enfermedad de Darier/terapia , Enfermedad de Darier/tratamiento farmacológico , Piel , Retinoides/uso terapéutico , Antibacterianos/uso terapéutico
4.
J Drugs Dermatol ; 22(10): 985-989, 2023 Oct 01.
Artículo en Inglés | MEDLINE | ID: mdl-37801530

RESUMEN

Keratosis pilaris (KP) is a chronic disorder of follicular hyperkeratinization and perifollicular erythema with lesions affecting the extensor surfaces of arms, upper legs, and buttocks. While there is some evidence that laser therapies and topical therapies such as lactic acid reduce the follicular papules of KP, support is limited with respect to which topical treatments dermatologists utilize and their perception of efficacy. A 16-question survey was distributed to a random sampling of the ODAC Conference listserv to determine which topical treatments dermatologists utilize the most, the duration of therapy needed with various treatment modalities, and the effectiveness of topical and laser therapy for treating KP. Our study found topical lactic acid is the most used first-line therapy for KP (43.63% of survey respondents), followed by salicylic acid (20.72%). Laser therapy is only utilized by 8.76% of survey respondents, with a lack of insurance coverage and proper equipment limiting its use. KP is often recalcitrant to treatment, and our study demonstrated that over 60% of respondents found recurrence of KP lesions within three months of stopping salicylic acid treatment and OTC moisturizer treatment. The data herein can be used to better utilize the selection of topical and laser therapies for the treatment of KP. J Drugs Dermatol. 2023;22(10):985-989 doi:10.36849/JDD.7534.


Asunto(s)
Enfermedad de Darier , Dermatólogos , Humanos , Enfermedad de Darier/diagnóstico , Enfermedad de Darier/terapia , Enfermedad de Darier/patología , Ácido Salicílico/uso terapéutico , Ácido Láctico
5.
Tidsskr Nor Laegeforen ; 143(5)2023 03 28.
Artículo en Inglés, Noruego | MEDLINE | ID: mdl-36987905

RESUMEN

Keratosis pilaris, or 'plucked chicken skin', is a very common condition. It is caused by keratin accumulation in the hair follicles. Although mild cases of the condition can be considered to be a normal variant, it can lead to multiple appointments with general practitioners and dermatologists. In rare cases, keratosis pilaris can form part of specific syndromes or be associated with other diseases. The aim of this article is to give an overview of the different variants of keratosis pilaris and discuss the pathogenesis and treatment options.


Asunto(s)
Anomalías Múltiples , Enfermedad de Darier , Humanos , Enfermedad de Darier/diagnóstico , Enfermedad de Darier/terapia , Cejas
6.
Dermatol Surg ; 46(11): 1397-1402, 2020 11.
Artículo en Inglés | MEDLINE | ID: mdl-32804891

RESUMEN

BACKGROUND: Keratosis pilaris (KP) is a common hereditary keratinization disorder. Keratosis pilaris rubra and KP atrophicans faciei are less frequent variants of the disease. Topical treatments often yield ineffective and temporary results. OBJECTIVE: The objective of this article is to review and assess all the studies that used light and laser devices to treat KP and its variants. MATERIAL AND METHODS: On January 15, 2017, an online search of the MEDLINE, Embase, and Cochrane databases was performed using the following combination of keywords: "keratosis pilaris" and "treatment." RESULTS: Seventeen studies related to light and laser treatments were retained for analysis. The total number of treated patients was 175. Of which, 22 patients had KP atrophicans faciei, 17 patients had KP rubra, and 136 patients had KP. CONCLUSION: Light and laser devices have been emerging as promising therapeutic options for a disfiguring disease that still lacks, until today, an effective long-term treatment.


Asunto(s)
Anomalías Múltiples/terapia , Enfermedad de Darier/terapia , Cejas/anomalías , Tratamiento de Luz Pulsada Intensa/métodos , Terapia por Luz de Baja Intensidad/métodos , Anomalías Múltiples/diagnóstico , Ensayos Clínicos como Asunto , Enfermedad de Darier/diagnóstico , Humanos , Tratamiento de Luz Pulsada Intensa/instrumentación , Láseres de Colorantes/uso terapéutico , Láseres de Gas/uso terapéutico , Láseres de Semiconductores/uso terapéutico , Láseres de Estado Sólido/uso terapéutico , Terapia por Luz de Baja Intensidad/instrumentación , Índice de Severidad de la Enfermedad , Resultado del Tratamiento
7.
J Cosmet Laser Ther ; 22(4-5): 174-176, 2020 Jul 03.
Artículo en Inglés | MEDLINE | ID: mdl-32654543

RESUMEN

Darier's disease is a rare genodermatosis typically characterized by scaly or crusted papules. Usual management comprises topical and oral treatments, however medical therapy may be inadequate in cases of severe disease. For these patients, further treatment options may include the use of carbon dioxide (CO2) laser therapy or surgical excision with skin grafting. We describe a unique situation in which both CO2 laser therapy and surgical excision were trialed in comparable areas within a single patient. Superior outcomes over a 7-year follow up period have been seen with the use of CO2 laser therapy.


Asunto(s)
Dióxido de Carbono/uso terapéutico , Enfermedad de Darier/terapia , Pie/patología , Terapia por Láser , Láseres de Gas , Humanos , Láseres de Gas/uso terapéutico , Piel/patología
8.
Adv Skin Wound Care ; 33(10): 1-4, 2020 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-32889820

RESUMEN

Darier disease is an autosomal dominant skin disorder characterized by keratotic papules. After their appearance, these lesions tend to grow over time, producing large and exudative plaques that compromise the general condition of the affected patient's skin. The authors report the clinical case of a patient affected by Darier disease with superinfected de-epithelialized areas over 30% of his body. In addition to antibiotic and antifungal therapy, providers used allograft skin to cover the injured areas and stimulate their progressive re-epithelialization with complete healing after 2 months. To the authors' knowledge, this is the first clinical case of treating Darier disease with allograft skin on an extensively damaged area. The effectiveness of this treatment may lead clinicians to consider allograft skin tissue a new, alternative dressing to treat Darier disease when this pathologic condition manifests with extensive eroded skin.


Asunto(s)
Aloinjertos/trasplante , Enfermedad de Darier/patología , Enfermedad de Darier/terapia , Trasplante de Piel , Anciano , Antibacterianos/uso terapéutico , Estudios de Seguimiento , Humanos , Masculino , Trasplante Autólogo
9.
Exp Dermatol ; 27(7): 795-797, 2018 07.
Artículo en Inglés | MEDLINE | ID: mdl-29604139

RESUMEN

Our purpose was accelerating the physiologic wound healing, stimulating tissue regeneration and the reparative tissue processes in resistant skin ulcers as in a case of an erosive lichen planus of the soles and after a surgical treatment as for severe Darier disease. The challenge was to establish an effective therapy to enhance tissue healing by the injection of a mixture of peripheral blood mononuclear cells (PB-MNCs) and platelet-rich plasma (PRP) into a skin autograft area. This new perioperative biotechnological approach enriches PRP with the effects of PB-MNCs. It offers a novel advanced strategy that could become an ideal biologic blood-derived therapy, whose components are entirely autologous and produced by a protocol independent by the operator.


Asunto(s)
Leucocitos Mononucleares/trasplante , Trasplante de Piel/métodos , Anciano de 80 o más Años , Terapia Combinada , Enfermedad de Darier/patología , Enfermedad de Darier/cirugía , Enfermedad de Darier/terapia , Femenino , Humanos , Liquen Plano/patología , Liquen Plano/cirugía , Liquen Plano/terapia , Persona de Mediana Edad , Plasma Rico en Plaquetas/citología , Regeneración , Úlcera Cutánea/patología , Úlcera Cutánea/cirugía , Úlcera Cutánea/terapia , Trasplante Autólogo/métodos , Cicatrización de Heridas
10.
Pediatr Dermatol ; 32(2): 234-6, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-24274972

RESUMEN

Phrynoderma is a type of follicular hyperkeratosis associated with nutritional deficiencies. It is rarely seen in developed countries, although cases have been reported in patients with severe malnutrition or malabsorption secondary to various causes. This report describes a 19-year-old patient with poorly controlled Crohn's disease and malnutrition who developed the characteristic hyperkeratotic papules and plaques on his trunk and extremities in the setting of low serum vitamin A levels. To our knowledge, there are no reports of phrynoderma associated with Crohn's disease. It is likely that our patient's low vitamin A level and subsequent phrynoderma was the result of increased Crohn's disease activity and malnutrition.


Asunto(s)
Enfermedad de Crohn/complicaciones , Enfermedad de Darier/complicaciones , Desnutrición/complicaciones , Deficiencia de Vitamina A/complicaciones , Biopsia con Aguja , Análisis Químico de la Sangre , Enfermedad de Crohn/diagnóstico , Enfermedad de Crohn/terapia , Enfermedad de Darier/diagnóstico , Enfermedad de Darier/terapia , Progresión de la Enfermedad , Humanos , Inmunohistoquímica , Masculino , Desnutrición/diagnóstico , Desnutrición/terapia , Enfermedades Raras , Medición de Riesgo , Deficiencia de Vitamina A/diagnóstico , Deficiencia de Vitamina A/terapia , Adulto Joven
13.
J Drugs Dermatol ; 12(7): 804-6, 2013 Jul 01.
Artículo en Inglés | MEDLINE | ID: mdl-23884495

RESUMEN

BACKGROUND: Current treatment options for keratosis pilaris (KP) are limited and are often found to be unsatisfactory to patients. OBJECTIVE: Pilot study to determine if photopneumatic therapy (PPx) can improve the erythema and skin texture in KP. METHODS: Ten patients with KP were treated with one session of PPx on the upper arm and then evaluated one month later for treatment efficacy. RESULTS: Average investigator-assessed improvement was 27% in erythema and 56% in skin texture roughness. Average patient self-reported improvement was 52% in erythema and 53% in skin texture. The mean satisfaction score was 6.3 on a scale of 1 to 10 (median 7.5) and 8 out of 10 participants reported they would choose to receive PPx for their KP again in the future. LIMITATIONS: Small number of patients, short follow-up period, and lack of blinding of the examiner and the patients making recall bias possible. CONCLUSIONS: One treatment of PPx improved both the erythema and redness associated with KP over at least a one month period.


Asunto(s)
Anomalías Múltiples/terapia , Enfermedad de Darier/terapia , Eritema/terapia , Cejas/anomalías , Fototerapia/métodos , Anomalías Múltiples/patología , Adolescente , Adulto , Enfermedad de Darier/patología , Eritema/etiología , Cejas/patología , Femenino , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Proyectos Piloto , Resultado del Tratamiento , Adulto Joven
14.
Artículo en Ruso | MEDLINE | ID: mdl-24605681

RESUMEN

AIM: Detection of features of functioning ofinnate and adaptive immunity pathways in patients with Darier erythema annulare centrifugum (EAC). MATERIALS AND METHODS: 14 EAC patients aged 14 - 52 years were examined. The patients were ranked based on therapy variant. The first group consisted of 6 patients who had received Immunovac-VP-4 (Immunovac) against the background of basic therapy; the second group (4 patients) received cagocel against the background of basic therapy; the third group (4 patients) received only basic therapy; the group of healthy individuals consisted of 15 individuals. All the patients had the level ofcytokines in blood sera determined by solid-phase EIA by using Biosource (Austria) test-systems. Evaluation of TLR expression in peripheral blood mononuclear lymphocytes and keratinocytes was carried out by flow cytometry method by using monoclonal antibodies (Catlag Laboratories, USA) against the corresponding antigens; evaluation of content of lymphocyte subpopulations in blood was carried out by using monoclonal antibodies by flow cytometry method on FacsCalibur flow cytometer (Becton Dickinson, USA). RESULTS: Immunotherapy by Immunovac and cagocel facilitated the increase of CD3+, CD4+, CD8+. Immunovac facilitated a significant increase ofinitially low values ofCD25+, CD95+ and normalization of CD72+; normalization of IgM level. Immunovac increased the level of serum IL-2, induced the increase of IFN-gamma synthesis in contrast to cagocel and basic therapy, the administration of those caused its decrease. TGF-beta increased during the course of Immunovac immunotherapy and decreased during basic therapy. In the course of basic therapy a significant increase of initially high level ofcytokine IL-I beta was observed. CONCLUSION: Immunovac therapy resulted in correction of content of lymphocyte populations, sera cytokines, facilitating the normalization of immunocompetent cell proliferation processes, activation of NK-cells, macrophages and at the same time suppression of DTH reactions. Immunovac facilitated the enhancement ofTLR3, 9 expression in the skin that indicates the inclusion ofintracellular receptor mechanisms of innate immunity.


Asunto(s)
Vacunas Bacterianas/administración & dosificación , Enfermedad de Darier , Eritema , Gosipol/análogos & derivados , Inmunidad Innata/efectos de los fármacos , Inmunoterapia , Adolescente , Adulto , Antígenos CD/sangre , Antígenos CD/inmunología , Antígenos de Diferenciación de Linfocitos B/sangre , Antígenos de Diferenciación de Linfocitos B/inmunología , Citocinas/sangre , Citocinas/inmunología , Enfermedad de Darier/sangre , Enfermedad de Darier/inmunología , Enfermedad de Darier/terapia , Eritema/sangre , Eritema/inmunología , Eritema/terapia , Femenino , Regulación de la Expresión Génica/efectos de los fármacos , Regulación de la Expresión Génica/inmunología , Gosipol/administración & dosificación , Humanos , Inmunoglobulina M/sangre , Inmunoglobulina M/inmunología , Interferón gamma/sangre , Interferón gamma/inmunología , Queratinocitos/inmunología , Queratinocitos/metabolismo , Linfocitos/inmunología , Linfocitos/metabolismo , Masculino , Persona de Mediana Edad , Receptor Toll-Like 3/biosíntesis , Receptor Toll-Like 3/inmunología , Receptor Toll-Like 9/biosíntesis , Receptor Toll-Like 9/inmunología , Vacunas Combinadas/administración & dosificación
15.
Ital J Dermatol Venerol ; 158(3): 217-223, 2023 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-37166753

RESUMEN

Keratosis pilaris (KP) is a common, hyperkeratotic skin condition characterized by small, folliculocentric papules with variable perifollicular erythema. We provide an updated review on the pathogenesis, clinical manifestations, and management of this common, and often annoying, finding. KP represents a family of follicular disorders, of which KP simplex is by far the most common. Other variants and rare subtypes include keratosis pilaris rubra, erythromelanosis follicularis faciei et colli, and the spectrum of keratosis pilaris atrophicans. Inherited mutations of the FLG gene and ABCA12 gene have been implicated etiologically. KP may be associated with ichthyosis vulgaris and palmar hyperlinearity, but less likely atopic dermatitis. Some potential differential diagnoses for KP include lichen spinulosus, phrynoderma, ichthyosis vulgaris, and trichostasis spinulosa. General cutaneous measures such as hydrating skin, avoiding long baths or showers, and using mild soaps or cleansers should be recommended. Topical keratolytic agents are first-line therapy, followed by topical retinoids and corticosteroids. Recent options include a variety of lasers and microdermabrasion if the patient is refractory to topical therapy.


Asunto(s)
Anomalías Múltiples , Enfermedad de Darier , Ictiosis Vulgar , Humanos , Ictiosis Vulgar/patología , Enfermedad de Darier/diagnóstico , Enfermedad de Darier/genética , Enfermedad de Darier/terapia , Piel , Anomalías Múltiples/diagnóstico , Anomalías Múltiples/patología
16.
Br J Dermatol ; 166(5): 1017-22, 2012 May.
Artículo en Inglés | MEDLINE | ID: mdl-22413864

RESUMEN

BACKGROUND: ATP2A2 encoding the sarcoplasmic/endoplasmic reticulum Ca(2+) -ATPase2 (SERCA2) is a Darier disease (DD)-related gene. Ultraviolet (UV) B irradiation downregulates ATP2A2/SERCA2 expression in keratinocytes, whereas cyclooxygenase-2 (COX-2) expression is dramatically upregulated by UVB. OBJECTIVES: To analyse the involvement of COX-2 in ATP2A2/SERCA2 expression. METHODS: Keratinocytes were transfected with COX-2 siRNA or treated with COX-2 inhibitor, celecoxib, to evaluate the effect of COX-2 on ATP2A2/SERCA2 expression. Quantitative real-time polymerase chain reaction, Western blotting analysis and reporter assay were used to determine the amount of mRNA, protein level and transcription activity, respectively. RESULTS: COX-2 knockdown by siRNA resulted in upregulation of ATP2A2 transcription. Treatment by celecoxib rescued UVB-mediated suppression of the ATP2A2 transcription and SERCA2 protein expression. Simple addition of prostaglandin (PG) E(2) , which is a product of COX-2 enzyme, reduced the amounts of ATP2A2 mRNA and SERCA2 protein in keratinocytes. CONCLUSIONS: UVB downregulates ATP2A2/SERCA2 expression via induction of COX-2 expression and subsequent increase of PGE(2) production in keratinocytes. Considering that DD is caused by the decreased function of SERCA2 due to the reduced expression of the ATP2A2 gene, this finding shows the possibility that COX-2 inhibition may be useful to prevent and/or treat DD.


Asunto(s)
Inhibidores de la Ciclooxigenasa 2/farmacología , Ciclooxigenasa 2/fisiología , Enfermedad de Darier/terapia , Queratinocitos/fisiología , ATPasas Transportadoras de Calcio del Retículo Sarcoplásmico/genética , Rayos Ultravioleta , Células Cultivadas , Dinoprostona/farmacología , Regulación hacia Abajo/efectos de los fármacos , Regulación hacia Abajo/efectos de la radiación , Técnicas de Silenciamiento del Gen , Humanos , Recién Nacido , Queratinocitos/efectos de los fármacos , Queratinocitos/metabolismo , ARN Interferente Pequeño/farmacología , ATPasas Transportadoras de Calcio del Retículo Sarcoplásmico/metabolismo
17.
Int J Hyperthermia ; 28(5): 451-5, 2012.
Artículo en Inglés | MEDLINE | ID: mdl-22690793

RESUMEN

BACKGROUND: Darier disease is an autosomal dominant hereditary skin disease that is susceptible to secondary bacterial or fungal infections, but rarely to human papillomavirus (HPV) infections. Multiple or extensive warts from HPV remain a therapeutic challenge, but local hyperthermia is effective. We treated a patient with Darier disease who had superimposed warts in the genital and neck regions. MATERIALS AND METHODS: The patient was treated with tolerable local hyperthermia with infrared light from a halogen lamp (surface temperature, 40°C) to a single target lesion on the genitalia (30 min daily) for 3 consecutive days. RESULTS: Within 2 weeks, the target lesion cleared and synchronous regression of untreated lesions on the neck was observed. CONCLUSIONS: In Darier disease, local hyperthermia treatment of HPV warts in 1 region was effective in treating multiple lesions, including lesions at a remote site, possibly by promoting an immune response against HPV.


Asunto(s)
Enfermedad de Darier/terapia , Hipertermia Inducida , Verrugas/terapia , Adulto , Humanos , Masculino , Cuello , Escroto
18.
Am J Dermatopathol ; 34(4): 449-51, 2012 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-22240774

RESUMEN

This case describes new onset mammary Paget disease arising in the background of Darier disease. Clinically and histologically, lesions of Darier disease can mask the lesions of mammary Paget disease. A high index of suspicion is necessary to diagnose Paget disease in a patient with Darier disease, for a potentially fatal disease could easily be missed.


Asunto(s)
Neoplasias de la Mama/diagnóstico , Enfermedad de Darier/diagnóstico , Enfermedad de Paget Mamaria/diagnóstico , Anciano , Biomarcadores de Tumor/análisis , Biopsia , Neoplasias de la Mama/química , Neoplasias de la Mama/complicaciones , Neoplasias de la Mama/terapia , Enfermedad de Darier/complicaciones , Enfermedad de Darier/terapia , Femenino , Humanos , Inmunohistoquímica , Queratina-7/análisis , Pezones/patología , Enfermedad de Paget Mamaria/química , Enfermedad de Paget Mamaria/complicaciones , Enfermedad de Paget Mamaria/terapia , Valor Predictivo de las Pruebas , Piel/patología
20.
J Dermatolog Treat ; 33(3): 1231-1242, 2022 May.
Artículo en Inglés | MEDLINE | ID: mdl-32886029

RESUMEN

INTRODUCTION: Keratosis pilaris (KP) is a common, benign skin condition of follicular hyperkeratosis. Although KP is asymptomatic, the cosmetic appearance of KP can lead to psychosocial distress among patients. New emerging treatments are increasingly being utilized. Yet, there is little to no summative data on the treatments of KP and its subtypes. OBJECTIVE: To summarize existing literature on treatments for KP and its subtypes. METHODS: A comprehensive search was performed using Pubmed/MEDLINE, Embase and Web of Science databases. The search identified 1150 non-duplicated articles, and 47 articles were included in the review. The primary outcomes measured were KP treatment type and the degree of improvement following therapy. FINDINGS: Our findings demonstrate that the most supported form of treatment for KP is laser therapy, particularly the QS:Nd YAG laser. Topical treatments - including Mineral Oil-Hydrophil Petrolat, tacrolimus, azelaic acid, and salicylic acid - are also effective at least for improving the appearance of KP. CONCLUSION: While the measured treatment outcomes varied among studies, laser therapy appears to be the most effective form of treatment. Use of topicals also improved KP lesions.


Asunto(s)
Anomalías Múltiples , Enfermedad de Darier , Terapia por Luz de Baja Intensidad , Anomalías Múltiples/terapia , Enfermedad de Darier/terapia , Cejas/anomalías , Humanos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA